Monopar Therapeutics
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
On* June 25, 2026,Quan Vu, our Chief Financial Officer, adopted a trading arrangement (the “Vu10b5*-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule10b5-1(c). The Vu Rule10b5-1 Trading Plan provides for the sale of up to 615 shares of Common Stock. The Vu Rule10b5-1 Trading Plan will terminate on* May 31, 2027,unless terminated earlier pursuant to the terms of the Vu Rule10b5*-1 Trading Plan.
On* June 25, 2026,Chandler Robinson, our Chief Executive Officer, adopted a trading arrangement (the “Robinson10b5*-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule10b5-1(c). The Robinson Rule10b5-1 Trading Plan provides for the sale of up to 47,309 shares of Common Stock. The Robinson Rule10b5-1 Trading Plan will terminate on* May 31, 2027,unless terminated earlier pursuant to the terms of the Robinson Rule10b5*-1 Trading Plan.
On* May 28, 2026,Christopher Starr, our Executive Chairman of the Board of Directors, adopted a trading arrangement (the “Starr10b5*-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule10b5-1(c). The Starr Rule10b5-1 Trading Plan provides for the sale of up to 16,800 shares of Common Stock. The Starr Rule10b5-1 Trading Plan will terminate on* February 20, 2027,unless terminated earlier pursuant to the terms of the Starr Rule10b5*-1 Trading Plan.
On* May 27, 2026,Kim Tsuchimoto, a member of the Board of Directors, adopted a trading arrangement (the “Tsuchimoto10b5*-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule10b5-1(c). The Tsuchimoto Rule10b5-1 Trading Plan provides for the sale of up to 16,360 shares of Common Stock. The Tsuchimoto Rule10b5-1 Trading Plan will terminate on* July 31, 2027,unless terminated earlier pursuant to the terms of the Tsuchimoto Rule10b5*-1 Trading Plan.
On* May 27, 2026,Patrice Rioux, our Chief Medical Director, adopted a trading arrangement (the “Rioux10b5*-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule10b5-1(c). The Rioux Rule10b5-1 Trading Plan provides for the sale of up to 1,380 shares of Common Stock. The Rioux Rule10b5-1 Trading Plan will terminate on* December 14, 2026,unless terminated earlier pursuant to the terms of the Rioux Rule10b5*-1 Trading Plan.
On* May 26, 2026,Raymond Anderson, a member of the Board of Directors, adopted a trading arrangement (the “Anderson10b5*-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule10b5-1(c). The Anderson Rule10b5-1 Trading Plan provides for the sale of up to 9,425 shares of Common Stock. The Anderson Rule10b5-1 Trading Plan will terminate on* May 31, 2027,unless terminated earlier pursuant to the terms of the Anderson Rule10b5*-1 Trading Plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.